With Karuna Therapeutics 14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio Analyst

KRTXDelisted Stock  USD 203.11  1.46  0.71%   
Slightly above 62% of Karuna Therapeutics' investor base is looking to short. The analysis of current outlook of investing in Karuna Therapeutics suggests that many traders are alarmed regarding Karuna Therapeutics' prospects. Karuna Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Karuna Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Earlier Friday, Bristol Myers Squibb Co agreed to acquire Karuna Therapeutics Inc for 330.00 per share in cash, for a total equity value of 14.0 billion, or 12.7 bill

Read at benzinga.com
benzinga news
  

Karuna Therapeutics Fundamental Analysis

We analyze Karuna Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karuna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karuna Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Short Ratio

Short Ratio Comparative Analysis

Karuna Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.

Karuna Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karuna Therapeutics stock to make a market-neutral strategy. Peer analysis of Karuna Therapeutics could also be used in its relative valuation, which is a method of valuing Karuna Therapeutics by comparing valuation metrics with similar companies.

Peers

Karuna Therapeutics Related Equities

INZYInozyme Pharma   9.56   
0%
100.0%
TERNTerns Pharmaceuticals   5.17   
0%
54.0%
MREOMereo BioPharma   1.58   
0%
16.0%
BPMCBlueprint Medicines   0.87   
0%
9.0%
XFORX4 Pharmaceuticals   0.45   
0%
4.0%
CYTKCytokinetics   0.14   
0%
1.0%
APLSApellis Pharmaceuticals   1.09   
11.0%
0%
DYNDyne Therapeutics   1.19   
12.0%
0%
DAWNDay One   1.86   
19.0%
0%
EWTXEdgewise Therapeutics   2.58   
26.0%
0%
ABOSAcumen Pharmaceuticals   3.56   
37.0%
0%
AMLXAmylyx Pharmaceuticals   7.58   
79.0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Other Consideration for investing in Karuna Stock

If you are still planning to invest in Karuna Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Karuna Therapeutics' history and understand the potential risks before investing.
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Transaction History
View history of all your transactions and understand their impact on performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format